Log in to search using one of your social media accounts:


Autologous Stem-Cell Transplantation for Severe Scleroderma

New England Journal of Medicine,Volume 378, Issue 11, Page 1066-1067, March 2018.
Source: New England Journal of Medicine - Category: Internal Medicine Source Type: research

Related Links:

PMID: 29654391 [PubMed - as supplied by publisher]
Source: Zeitschrift fur Rheumatologie - Category: Rheumatology Authors: Tags: Z Rheumatol Source Type: research
British Journal of Dermatology,Volume 178, Issue 3, Page e239-e239, March 2018.
Source: British Journal of Dermatology - Category: Dermatology Source Type: research
Systemic sclerosis: Autologous HSCT is efficacious, but can we make it safer?, Published online: 08 March 2018; doi:10.1038/nrrheum.2018.34Autologous haematopoietic stem cell transplantation (HSCT) has proved efficacious in treating patients with systemic sclerosis, but different regimens have different associated toxicities and different effects on lung function. Through comparison of different clinical trials, we can learn how to improve the safety of HSCT.
Source: Nature Reviews Rheumatology - Category: Rheumatology Authors: Source Type: research
Myeloablative autologous hematopoietic stem cell transplantation resulted in significantly better long-term clinical outcomes —although greater toxicity–in patients with scleroderma than did cyclophosphamide, found atrial published in theNew England Journal of Medicine.
Source: JAMA - Category: General Medicine Source Type: research
CONCLUSIONS: Reactivity towards topo-I-epitopes is heterogeneous in SSc, but peptide 39 (aa647-671) may be another immunodominant epitope besides the published epitope aa489-573. Antibody reactivity to this peptide 39 was higher in group 2- than in group 1-patients. Peptide recognition pattern did not change after aSCT. PMID: 29465357 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
In this study, 36 people with severe scleroderma received stem-cell transplantation and were compared with 39 otherwise similar people who received a year of standard immune-suppressing medication. After 4.5 years, those assigned to receive stem-cell transplantation had improved overall survival compared with standard treatment (79% vs. 50%) less need for immune-suppressing medication (9% vs. 44%) fewer deaths related to worsening scleroderma (11% vs. 28%) more deaths related to treatment — (3% vs. 0%). These findings suggest that stem-cell transplantation may be much better than standard treatment for people with ...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Autoimmune diseases Health Skin and Hair Care Source Type: blogs
• A meta-analysis comparing autologous HSCT to immunosuppression in system sclerosis• Transplantation is associated with a reduction in overall mortality• Transplantation is associated with an improvement in skin thickness, lung function, and quality of life• Autologous SCT is a Disease-Modi fying Anti-Rheumatic Treatment for systemic sclerosis
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
International Journal of Rheumatic Diseases, EarlyView.
Source: APLAR Journal of Rheumatology - Category: Rheumatology Source Type: research
Conclusions Changes in CT-textural features after SCT are associated with visual CT evaluation of SSc-related lung abnormalities, but complementary provide information about therapy-induced, structural pulmonary changes.
Source: European Journal of Radiology - Category: Radiology Source Type: research
British Journal of Dermatology, EarlyView.
Source: British Journal of Dermatology - Category: Dermatology Source Type: research
More News: Internal Medicine | Scleroderma | Stem Cell Therapy | Stem Cells | Transplants